Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPEL-36: bempegaldesleukin + pembrolizumab vs pembrolizumab in first-line PD-L1-positive recurrent/metastatic HNSCC
NL-OMON49921Phase 2Withdrawn
- Sponsor
- Nektar Therapeutics
- Start
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing Bempegaldesleukin plus pembrolizumab with Pembrolizumab monotherapy (2 arms). Primary endpoints: Overall survival and Objective response rate. Planned start Oct 2021; status: withdrawn.
02
Drugs
bempegaldesleukinpembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON49921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49921.